ijms-logo

Journal Browser

Journal Browser

Steroidal Anticancer Agents for Treating Gynecological Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 2486

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary
Interests: steroidal anticancer agents; cell cycle blockade; antimetastatic activity; tubulin polymerization; metastasis pathways; HPV-associated cancer
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Organic Chemistry, University of Szeged, Dóm tér 8, H-6720 Szeged, Hungary
Interests: steroid synthesis; core modification; secosteroids; homosteroids; molecular mechanics; molecular dynamics; drug design
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nearly 60 years ago the first scientific article about cancer cell proliferation inhibiting effect of cardiac glycosides was published. Since then the scientific interest has not declined in connection with novel anticancer agents with widely modifiable sterane skeleton. Thanks to the permanent and intensive research work in this field, numerous steroidal anticancer agents (e.g., fulvestrant, estramustin, cyproterone and exemestane) have become significant members of antitumor protocols. In addition, substantially diverse anticancer mechanisms of action have been described such as steroidal receptor antagonism, enzyme inhibition and surprising direct antiproliferative activity as well as promising inhibitory effect on multi-drug resistance. Therefore, these molecules still deserve outstanding attention in the field of anticancer research.

This Special Issue of the International Journal of Molecular Sciences entitled “Steroidal Anticancer Agents for Treating Gynecological Cancer”, will focus on recent advances in newly synthesized compounds with sterane skeleton and their anticancer effect, such as structure-activity relationships, molecular mechanism of antitumor and antimetastatic effect, mechanisms of multi-drug resistance reversal features and investigation of the structural background of the anticancer activitiy at atomic level using computational simulation. Contributions on these related topics are welcomed, including original research and full reviews. We also very much welcome tasks of postdocs, PhD students, and young researchers.

Dr. Renáta Minorics
Dr. Erzsébet Mernyák
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast/ovarian/cervical/endometrial cancer
  • synthetic/semi-synthetic analogues
  • structure determination
  • estrane/pregnane/androstane derivatives
  • cell cycle arrest
  • cell death induction
  • tubulin-microtubule system
  • intracellular/membrane steroid hormone receptors
  • metastasis signaling pathway
  • structure-activity relationship
  • computational simulation
  • molecular docking/modeling
  • multi-drug resistance reversal effect
  • in vitro and in vivo approach
  • enzyme inhibition

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 15772 KiB  
Article
Investigation of the Antineoplastic Effects of 2-(4-Chlorophenyl)-13α-Estrone Sulfamate against the HPV16-Positive Human Invasive Cervical Carcinoma Cell Line SiHa
by Hazhmat Ali, Péter Traj, Gábor J. Szebeni, Nikolett Gémes, Vivien Resch, Gábor Paragi, Erzsébet Mernyák, Renáta Minorics and István Zupkó
Int. J. Mol. Sci. 2023, 24(7), 6625; https://doi.org/10.3390/ijms24076625 - 1 Apr 2023
Cited by 3 | Viewed by 2196
Abstract
Cervical carcinoma is one of the most frequent malignant gynecological cancers in women of reproductive age. Because of the poor tolerability of currently available chemotherapeutic agents, efforts have been focused on developing innovative molecules, including steroids, that exert antineoplastic effects with a better [...] Read more.
Cervical carcinoma is one of the most frequent malignant gynecological cancers in women of reproductive age. Because of the poor tolerability of currently available chemotherapeutic agents, efforts have been focused on developing innovative molecules, including steroids, that exert antineoplastic effects with a better safety profile. In addition to their endocrine properties, certain estrogens exhibit additional biological activities, such as antiangiogenic and anticancer effects. Based on previous studies, the antineoplastic properties of 13α-estrone sulfamate derivatives (13AES1-3) were investigated, and the mechanism of action for the most promising compound 13AES3 was explored. Based on their effects on the viability of different human adherent gynecological cancer cells, the SiHa cervical cell line was used for mechanistic experiments. The most active analog 13AES3 was shown to exert considerable proapoptotic effects, as evidenced by a colorimetric caspase-3 assay and fluorescent double staining. It also elicited antimigratory and anti-invasive effects in a concentration-dependent manner, as evidenced by wound healing and Boyden chamber assays, respectively. Regarding their mechanism of action, 13AES derivatives were shown to inhibit tubulin polymerization, and computer simulations provided a possible explanation for the importance of the presence of the chlorophenyl ring on the estrane skeleton. 13AES3 is considered to be the first 13α-estrone derivative with a significant antineoplastic potency against SiHa cancer cells. Therefore, it might serve as a valuable lead molecule for the design of anticancer agents targeting cervical carcinomas. Full article
(This article belongs to the Special Issue Steroidal Anticancer Agents for Treating Gynecological Cancer)
Show Figures

Graphical abstract

Back to TopTop